NCT07562152
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07562152
Title Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (MAPKeeper 301)
Acronym MAPKeeper 301
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immuneering Corporation
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ROU | POL | HUN | GBR | ESP | DEU | AUS


No variant requirements are available.